Last reviewed · How we verify
NCT04021069
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
trial testing Radiomic, pathomic, and clinical markers in Breast Cancer in 800 participants. Status unknown.
30 December 2019
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 30 August 2018 |
| Primary completion | 30 December 2019 |
| Estimated completion | 30 August 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Radiomic, pathomic, and clinical markers
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Invasive Ductal Breast Carcinoma — all drugs for Invasive Ductal Breast Carcinoma →
- Invasive Lobular Breast Carcinoma — all drugs for Invasive Lobular Breast Carcinoma →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Invasive Ductal Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04021069
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiomic, pathomic, and clinical markers
Trials testing the same drug.
- NCT04086849 — Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04021069 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 16 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04021069.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing